Literature DB >> 8641036

Biological response to Bard Clamshell Septal Occluders in the canine heart.

M A Kuhn1, L A Latson, J P Cheatham, B McManus, J M Anderson, K L Kilzer, J Furst.   

Abstract

BACKGROUND: The Clamshell Septal Occluder has been used to close various congenital heart defects. The purpose of this study was to evaluate the long-term biological response to this device after placement in the canine heart. Previous in vivo studies with device placement were limited to 60 days. METHODS AND
RESULTS: An atrial septal defect was created in dogs by blade septostomy followed by balloon dilation. Both old and new (redesigned) devices were placed. Angiographic follow-up was performed at 1, 3, and 6 months and 1 and 2 years after device placement with groups of dogs euthanitized at the same intervals. Gross and microscopic assessment was done on the explanted devices. The implants were covered at least 50% by neointima at 1 month and covered completely by 3 months. There was no thrombus formation. Areas of focal hemorrhage were evident at 1 month and were not present at 3 months. The fibrous capsule that covered the device became more densely organized and neovascularized by 2 years. A focal foreign body reaction at the device-tissue interface persisted for 2 years. There were no arm fractures with either the old or new devices in these dogs.
CONCLUSIONS: The Bard Clamshell Septal Occluder is well tolerated in the canine heart for at least 2 years and elicits a normal healing process.

Entities:  

Mesh:

Year:  1996        PMID: 8641036     DOI: 10.1161/01.cir.93.7.1459

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

Review 1.  Atrial septum defect closure device in a beating heart, from the perspective of a researcher in artificial organs.

Authors:  Yasuko Tomizawa
Journal:  J Artif Organs       Date:  2012-06-23       Impact factor: 1.731

Review 2.  Antiplatelet therapy in valvular and structural heart disease interventions.

Authors:  Annunziata Nusca; Edoardo Bressi; Iginio Colaiori; Marco Miglionico; Germano Di Sciascio
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

3.  Transcatheter closure of atrial septal defects using the Cardio-Seal implant.

Authors:  C A Pedra; J Pihkala; K J Lee; C Boutin; D G Nykanen; P R McLaughlin; D A Harrison; R M Freedom; L Benson
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

4.  Biocompatibility of septal defect closure devices.

Authors:  Matthias Sigler; Christian Jux
Journal:  Heart       Date:  2006-10-11       Impact factor: 5.994

5.  Animal experimental implantation of an atrial septal defect occluder system.

Authors:  A Bloch Thomsen; M Schneider; U Baandrup; E V Stenbøg; J M Hasenkam; J P Bagger; G Hausdorf
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 6.  Role of animal models for percutaneous atrial septal defect closure.

Authors:  Zakaria Jalal; Pierre-Emmanuel Seguela; Alban-Elouen Baruteau; David Benoist; Olivier Bernus; Olivier Villemain; Younes Boudjemline; Xavier Iriart; Jean-Benoit Thambo
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

7.  Assessment of Device Neoendothelialization With Cardiac Computed Tomography Angiography After Transcatheter Closure of Atrial Septal Defect.

Authors:  Ah Young Kim; Wongi Woo; Beom Jin Lim; Jo Won Jung; Jae Young Choi; Young Jin Kim
Journal:  Circ Cardiovasc Imaging       Date:  2022-07-19       Impact factor: 8.589

8.  Transapical mitral valve implantation: the Lutter valve.

Authors:  G Lutter; S Pokorny; D Frank; J Cremer; L Lozonschi
Journal:  Heart Lung Vessel       Date:  2013

9.  Key Regulatory Differentially Expressed Genes in the Blood of Atrial Septal Defect Children Treated With Occlusion Devices.

Authors:  Bo-Ning Li; Quan-Dong Tang; Yan-Lian Tan; Liang Yan; Ling Sun; Wei-Bing Guo; Ming-Yang Qian; Allen Chen; Ying-Jun Luo; Zhou-Xia Zheng; Zhi-Wei Zhang; Hong-Ling Jia; Cong Liu
Journal:  Front Genet       Date:  2021-12-08       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.